Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Study of CKD-393 in Healthy Volunteers Under Fed Conditions
NCT05113693Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Nov 2021
- Primary completion
- Dec 2021
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CKD-393 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Curve from time 0 to the last measurable concentration at 48 hours and Maximum Plasma Concentration at 48 hours. Started Nov 2021; status: completed.
02
Drugs
CKD-393
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05113693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05113693.